By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Esperance Pharmaceuticals, Inc. 

Louisiana Emerging Technology Center
340 East Parker Boulevard
Baton Rouge  Louisiana  70803  U.S.A.
Phone: n/a Fax: 225-615-8952


SEARCH JOBS


Industry
Pharmaceutical






Company News
Esperance Pharmaceuticals, Inc. Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer 8/28/2012 10:50:38 AM
Esperance Pharmaceuticals, Inc. Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at American Society of Clinical Oncology 6/4/2012 10:32:46 AM
Esperance Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of its Novel Membrane-disrupting Agent, EP-100, in Patients with Advanced Ovarian Cancer 5/18/2012 10:57:07 AM
Esperance Pharmaceuticals, Inc. Presents Poster at American Association for Cancer Research Annual Meeting Demonstrating Synergy of Lead Candidate EP-100 with Paclitaxel in In Vitro Studies 4/3/2012 11:15:25 AM
Esperance Pharmaceuticals, Inc. Completes $7.5 Million Series B Financing 6/1/2011 6:35:34 AM
Third Candidate from <Esperance Pharmaceuticals, Inc.'s Targeted Anti-cancer Platform, EP-302, Establishes Preclinical Proof of Concept 4/21/2010 10:06:02 AM
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 9/10/2009 8:05:35 AM
First Candidate from Esperance Pharmaceuticals's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 4/22/2009 8:29:38 AM
Esperance Pharmaceuticals Brings Series A To $14 Million 2/6/2009 11:05:35 AM
Esperance Pharmaceuticals Closes $9 Million Series A Funding 10/31/2006 9:47:03 AM
//-->